Overview

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The aims of this protocol are: 1. To study the safety and tolerability of the combination of etanercept and gemcitabine in patients with advanced pancreatic cancer: 2. To estimate the anti-tumor effect as measured by the proportion of patients free of disease-progression at six months after treatment initiation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborator:
Immunex Corporation
Treatments:
Etanercept
Gemcitabine